INTRODUCTION
The NMDA receptor hypofunction hypothesis of schizophrenia was established after the observation that NMDA receptor antagonists such as phencyclidine (PCP) and ketamine can induce, in healthy individuals, altered behavioral states that resemble the positive and negative symptoms as well as the cognitive deficits seen in schizophrenia [1] [2] [3] . In addition, ketamine can heighten psychotic episodes in patients with schizophrenia [4] [5] [6] . In rodents, PCP and the more potent and selective noncompetitive NMDA receptor antagonist, dizocilpine (MK-801), cause hyperlocomotion and stereotypies [7] [8] [9] . The hyperactivity is considered to be due predominantly to activation of D 2 receptors in the nucleus accumbens, whereas stereotypies are caused by stimulation of D 2 receptors in the caudate-putamen [10] . These behaviors have been potentially related to positive symptoms of schizophrenia [11] [12] [13] . Acute NMDA receptor antagonism has also been reported to increase the release of glutamate [14] [15] [16] [17] [18] , dopamine [19, 20] , and serotonin (5-HT) [8, 16-18, 21, 22] in the medial prefrontal cortex (mPFC). It has been proposed that stimulation of NMDA receptors on the GABA inhibitory interneurons within the cortex leads to the release of GABA, which would inhibit glutamatergic neurons and the subsequent release of glutamate. Blockade of such NMDA receptors would therefore decrease GABAergic inhibitory tone and result in an enhanced activity of pyramidal neurons within the cortex [14, 23, 24] leading to downstream changes in other transmitters. Indeed, GABAergic interneurons in limbic cortex and hippocampus are more sensitive than pyramidal neurons to the action of NMDA receptor antagonists [25, 26] . In addition, reduced GABAergic function would alter the synchronous firing patterns of cortical neurons, which may underlie information-processing deficits present in patients with schizophrenia [27] .
Various studies have demonstrated that the interactions among dopamine, 5-HT and glutamate play an important role in the pathophysiology of schizophrenia and that receptors for these transmitters are involved in the action of antipsychotic drugs. Increased activity of the mesolimbic dopamine system is believed to underlie the positive or psychotic symptoms of schizophrenia and decreased activity within the mesocortical dopamine system is believed to reflect negative symptoms and cognitive function also seen in this illness [28] [29] [30] [31] [32] . All available antipsychotic drugs posses some degree of dopamine D 2 /D 3 receptor antagonism, and blockade of dopamine D 2 /D 3 receptors within the mesolimbic pathway reduces psychotic symptoms [33] . As a matter of fact, a good correlation exists between the clinical efficacy of antipsychotic drug and their affinity for D 2 receptor [34, 35] . Furthermore, most antipsychotic drugs display a dose-dependent threshold of D 2 /D 3 receptor occupancy for their therapeutic effects [36] . However, the necessity of D 2 /D 3 receptor blockade for therapeutic action has been challenged recently by the finding that drugs that attenuate glutamate release, without acting directly on dopamine receptors, are beneficial for positive and negative symptoms [37] .
Several atypical antipsychotic drugs, on the other hand, are characterized by a lower affinity for D 2 /D 3 and higher affinity for 5-HT 2A receptors, which has been proposed to confer a superior efficacy and tolerability [38, 39] . The lower occupancy of dopamine D 2 /D 3 receptors appears to be responsible for causing fewer extrapyramidal side-effects (EPS) [40] . In addition to the predominant role of the D 2 /D 3 receptor in the current treatment of psychotic symptoms, dopamine D 1 receptors have been implicated in schizophrenia [41, 42] . This line of evidence has been recently highlighted by the finding that cognitive/negative symptoms in schizophrenia are associated with a reduction of prefrontal dopamine D 1 receptor binding [43] . Some atypical antipsychotic drugs may also have affinity for other transmitter receptors such as serotonin 5-HT 1A , α-adrenergic, histamine H 1 , and muscarinic receptors, which may affect their efficacy and side-effect profile [44, 45] . Thus, there is some evidence for the importance of 5-HT 1A receptor agonists in certain aspects of the pharmacotherapy of schizophrenia [46] [47] [48] [49] . Furthermore, 5-HT 1A receptor agonists have been shown to reduce the incidence of EPS in schizophrenia patients treated with haloperidol [50, 51] . With regard to α-adrenergic mechanisms, many clinically effective antipsychotic drugs (both classical and atypical) possess α 1 -adrenoceptor antagonist properties [44, 52] , which has been postulated to be clinically relevant [53] . However, although central α 1 -adrenoceptors may regulate sensorimotor gating altered in schizophrenia [54] , there are not studies dealing with the occupancy of α 1 -adrenoceptors in individuals under antipsychotic treatment.
In the animal setting, most studies have shown that atypical, but not typical, antipsychotics block the effects of NMDA receptor antagonists on prepulse inhibition (PPI) of the startle response [55] . In addition, atypical antipsychotic drugs, but not haloperidol, increases extracellular DA concentration in the PFC [56, 57] and prevent the brain increase in regional 2-deoxyglucose uptake induced by ketamine [58] . We have shown recently that the local perfusion of antipsychotic drugs decreased extracellular 5-HT in the mPFC [59, 60] . Stimulation of 5-HT 1A and blockade of 5-HT 2A receptors might contribute to this effect since both types of compounds were able to prevent the increases in 5-HT and glutamate, as well as cognitive deficits induced by NMDA receptor antagonists [16, 17, 61, 62] . In contrast, raclopride and eticlopride prevented the increase of glutamate (but not that of 5-HT) induced by MK-801 [62] . Furthermore, clozapine and haloperidol attenuated PCP-induced increase in cortical glutamate [63] , as well as the elevated firing of a population of mPFC pyramidal neurons elicited by PCP or MK-801 [64, 65] . Interestingly, clozapine exhibited a leveling effect on the firing of pyramidal cells in the mPFC, increasing the activity of neurons with low baseline firing rates and decreasing the activity of neurons with higher firing rates [64] . This fine-tuning effect might contribute to the unique therapeutic efficacy of clozapine in schizophrenia.
In a previous study we showed that both clozapine and haloperidol blocked the MK-801-induced increase in glutamate in rat mPFC, whereas only clozapine was able to block the increased efflux of 5-HT [18] . In addition, we also showed that antagonism at dopamine D 2 receptors and agonism at dopamine D 1 receptors resulted in blockade of the effects of MK-801 on mPFC glutamate but not 5-HT. In contrast, 5-HT 2A and α 1 -adrenergic receptor antagonists, as well as 5-HT 1A receptor agonist, were able to prevent the increase in 5-HT and glutamate elicited by MK-801 [62] . In the present study we set out to replicate such findings using a wider range of concentrations and extend them to other typical (chlorpromazine) and atypical (olanzapine) antipsychotic drugs. To this end, intracerebral microdialysis in the mPFC was used under the same experimental conditions described previously [18, 63] .
The choice of prefrontal cortex was accounted for by its pivotal involvement in higher brain functions such as executive tasks and cognition [66] known to be disrupted in schizophrenia [67] and in animal models [68] . Despite the importance of mPFC in the etiology and pharmacotherapy of schizophrenia, it is worth noting that the effects of such compounds in other brain regions may also be crucial for the treatment of the illness. From a methodological point of view it is also important to note that antipsychotic drugs and selective compounds were delivered in the mPFC by reverse dialysis. Despite the in vitro affinity (10 -8 -10 -9 M) of antipsychotics and selective compounds used in the present study for serotonergic and adrenergic receptors, the use of concentrations in the micromolar range is required in in vivo microdialysis to significantly affect neurotransmitter receptors (e.g. [69, 70] ). This is due to the fact that effective concentration at receptors is limited by the low application rate (in the low nmol/h range) and the continuous clearance of the applied drug by the cerebrospinal fluid. Moreover, a substantial number of post-synaptic receptors in mPFC neurons must be recruited to activate/inhibit the mPFC-raphe circuit and elicit changes in mPFC 5-HT release [71, 130] .
IS CORTICAL 5-HT TRANSMISSION RELATED TO "ATYPICALITY"?
The term "atypical" referred to an antipsychotic drug was first applied to clozapine because this drug was devoid of the overt EPS and increased prolactin secretion seen in humans treated with neuroleptics. By comparison with the pharmacological profile of clozapine, it is considered that atypical antipsychotic drugs are relatively more potent serotonin 5-HT 2A antagonists than dopamine D2 antagonists (see [39] for review). More recently, the multireceptor pharmacology of atypical antipsychotics has included other features such as serotonin 5-HT 1A and dopamine D1 agonism, dopamine D2 partial agonism as well as α 1 -adrenergic antagonism [46, 53, 72, 73] .
The effects of antipsychotic drugs on extracellular 5-HT in the mPFC are far from conclusive [18, 61, 74, 75] . In general, both typical and atypical antipsychotics seem to decrease or leave unchanged cortical 5-HT although the particular effect might depend on the experimental conditions and/or dose of the drug. However, there seems to be a concurrence of results showing that risperidone increases cortical dialysate 5-HT, an effect which is probably related to its antagonistic action at α 2 -adrenoceptor, and seems to take place at the nerve terminal level [74] . In line with this assumption, Hertel and coworkers [76] demonstrated that idazoxan, an Previous studies have demonstrated that NMDA receptor antagonists augment the firing rate of putative pyramidal neurons within the mPFC [65, 77, 78] , which results in an increased efflux of glutamate and 5-HT. These effects are accounted for by an overstimulation of cortical AMPA-dependent glutamatergic transmission because they were abolished by intra-mPFC perfusion of an AMPA receptor antagonist [18, 79] . In line with previous research [8, 14, 15] , MK-801 increases glutamate release onto AMPA/kainate receptors leading to an enhanced glutamatergic output from mPFC neurons (including those projecting to the dorsal raphe nucleus) thereby increasing serotonergic cell firing and cortical 5-HT release. Furthermore, it has been shown that blockade of AMPA/kainate receptors in the prefrontal cortex inhibited PCP-induced locomotion and stereotypy [80] . The antipsychotic action would therefore result from a prevention of the effects resulting from this cortical hyperglutamatergia.
In an initial study carried out in our lab we showed that pretreatment with atypical antipsychotic drugs such as clozapine and olanzapine suppressed the increased release of 5-HT in the mPFC elicited by phencyclidine (PCP) and ketamine whereas haloperidol failed to do so [22] . Subsequently we demonstrated that clozapine and haloperidol were able to block the increase in cortical glutamate produced by MK-801, but only clozapine reduced the increase in 5-HT [18] . In addition, the mPFC appeared to be the preferential site of action of these drugs inasmuch as their effects were seen after local infusion through a dialysis probe. As shown in Fig 
EFFECTS OF DOPAMINERGIC COMPOUNDS
In accord with our hypothesis, we have shown that two different dopamine D2 receptor antagonists, raclopride and eticlopride, elicited the same effect than that of haloperidol and chlorpromazine ( [62] ; present study). Raclopride binds with equal affinity to D 2 and D 3 receptors and has negligible affinity for D 4 receptors [85] , and eticlopride possesses equal selectivity for D 2 and D 3
receptors [86] , but 10-fold greater affinity than raclopride for both receptors [87] .
Eticlopride also interacts with D 4 receptors [83] . Further, tyrosine hydroxylase-positive terminals have been observed in apposition with GABA interneurons [94, 95] . Among the different types of cortical GABA interneurons, it has been shown that dopamine acts almost exclusively on those containing parvalbumin (PV) [92, 96] , which target the perisomatic compartment of pyramidal cells [97, 98] . In addition, immunocytochemistry studies have reported that PV interneurons express both dopamine D 1 and D 2 receptors [92] . From a physiological viewpoint, dopamine exerts a tonic inhibitory action on PV interneurons through D2 receptors [99, 100] . In addition, evidence from a postmortem study has indicated that, in the anterior cingulate cortex of schizophrenics, there is a shift of dopaminergic terminals from pyramidal cells to GABA interneurons [101] . This dopamine could then act on D2 receptors located in these interneurons thereby reducing the release of GABA with the subsequent disinhibition of pyramidal cells. In the animal model setting that we used, an excessive release of dopamine following MK-801 administration [19] might lead to a further reduction in GABAergic inhibition, which would result in an impairment of the intrinsic cortical circuitry. In fact, this has been postulated to occur in the brain of schizophrenics [102] [103] [104] . (Fig (3) ). Although there is histological evidence of the presence of dopamine D 4 receptors in the mPFC of rodents, controversy exists as regards to the level of expression [91, [111] [112] [113] [114] [115] . There is consensus, however, that the prefrontal cortex depicts a prominent expression of this receptor [91, 110, 114, 115] , which is expressed in both pyramidal and GABAergic cells [91, 110, 114] . Our results are consistent with a localization of dopamine D 4 receptors in GABAergic interneurons although it remains to be determined the phenotype of such cells.
The regulation of prefrontal function by dopamine involves not only D2, but also D1 receptors. In fact, dopamine D1 agonists enhance cortical dopaminergic transmission, which is postulated to be good against cognitive and negative symptoms [116] . Indeed, the systemic administration of a low dose of a dopamine D1 receptor agonist ameliorates cognitive dysfunction induced by MK-801 although increases stereotypy and locomotor activity (model of psychotic symptoms) at higher doses [117] . Our results show that dopamine D1 agonism elicits comparable effects to those of dopamine D2
antagonists, i.e. a reduction of MK-801-induced increase of cortical glutamate [62] . However, when the concentration of the dopamine D1 agonist, SKF-38393, was increased to 100 µM, the elevation of 5-HT elicited by MK-801 was abolished (Fig (4) ). However, it remains to be determined the potential clinical interneurons that influence mPFC output to the raphe nuclei (Fig (8) ).
Altogether our results suggest that D2 antagonists and D1 agonists might end up with the same response, i.e. to restore cortical GABA efflux in order to prevent an excessive glutamatergic transmission following MK-801 administration. Furthermore, our results are also consistent with the proposal that D1 receptor activation requires phasic dopamine release whereas D2 receptors are continuously driven by basal, tonic dopamine release [122] .
EFFECTS OF SEROTONERGIC COMPOUNDS
In contrast to dopamine D2 receptor antagonists, the selective 5-HT 2A
antagonist, M100907 [123] , prevented the increase in 5-HT and glutamate elicited by MK-801 in a concentration-dependent manner (Fig (5) ). This agrees with prior work using a competitive NMDA receptor antagonist [16] Besides 5-HT 2A receptor antagonism, 5-HT 1A receptor agonism is also able to block the increase in 5-HT and glutamate elicited by MK-801 with a comparable potency (Fig (6) ). Another study has shown that the 5-HT 1A receptor agonist 8-OH-DPAT also prevents the increase in cortical 5-HT and glutamate evoked by a competitive NMDA antagonist [17] . As for the effects of M100907, the reduction of 5-HT is probably caused by a decrease in the activity of pyramidal cells projecting to the DR [128, 129] , which would ease this nucleus from a tonic excitatory input, thereby decreasing the activity of 5-HT cells [130] . The 5-HT 1A receptor agonist repinotan (BAY x 3702) [131] has proved also effective in blocking the increased 5-HT release induced by intramPFC perfusion of S-AMPA, DOI and cirazoline [59, 124] , as well as thalamic disinhibition [60] . 
EFFECTS OF α 1 -ADRENOCEPTOR ANTAGONISTS
As for 5-HT 2A antagonists and 5-HT 1A agonists, the intra-mPFC administration of the α 1 -adrenoceptor antagonist prazosin [134] also blocked the MK-801-induced increase in 5-HT and glutamate (Fig (7) ). Although adrenergic receptors is that the latter are separated in two bands around layer V [139, 140] . In line with the present work, previous studies carried out in our laboratory have revealed that the perfusion of prazosin in the mPFC prevented the increase of 5-HT elicited by the cortical application of cirazoline, DOI and S-AMPA [60] , as well as thalamic disinhibition [60] . Because all these compounds do not interact directly with each other's receptors their effects need to be interpreted not at receptorial level, but at cellular (pyramidal) level. This is correspondence with the role of pyramidal cells of the mPFC in integrating multiple inputs from cortical as well as subcortical areas [141] [142] [143] .
IMPLICATIONS FOR ANTIPSYCHOTIC ACTION
The findings of the present and previous [18, 62] However, olanzapine was the medication that patients stayed on the longest in the trial [144] . In similar terms, the Cost Utility of the Latest Antipsychotics in
Severe Schizophrenia (CUtLASS) study also concluded that second-generation (atypical) antipsychotics do not offer significant clinical benefits over firstgeneration (typical) drugs when prescribed to patients with schizophrenia [145] .
Altogether these studies illustrate the difficulty of translating from experimentally-observable pharmacological differences in the preclinical setting to therapeutic advantages. [128, [146] [147] [148] [149] [150] [151] [152] . Atypical antipsychotic drugs that exhibit 5-HT 2A
antagonism and/or 5-HT 1A agonism, such as clozapine, increase dopamine efflux in the mPFC of rodents [57, [153] [154] [155] [156] [157] , which is potentially involved in the improvement of negative symptoms and cognitive dysfunction in schizophrenia [154, 155, 158, 159] . This effect appears to be dependent on the presence of intact 5-HT 1A receptors [57, 157] . Given that some of these drugs (e.g. olanzapine) do not depict affinity for 5-HT 1A receptors ( Table 1) , it would seem that the 5-HT 1A receptor has a permissive role in this action, rather than being directly responsible. However, the increase in dopamine efflux produced by atypical antipsychotic drugs, including olanzapine, is inhibited by the 5-HT 1A
receptor antagonist WAY 100635 [155] and absent in 5-HT 1A receptor knockout mice [57] , which suggests a pivotal role for 5-HT 1A agonism in some of the key properties desired for novel antipsychotic drugs. This concept is supported by clinical trials with partial 5-HT 1A receptor agonists, which report the ability of these compounds not only to reduce the incidence of EPS [46] but also to enhance some domains of cognitive function [47] . However, inconsistent results have been found depending on the antipsychotic drug and the 5-HT 1A receptor agonist used (reviewed in [160] ).
With regard to α 1 -adrenoceptors, preclinical studies have revealed that the blockade of α 1 -adrenoceptors by prazosin potentiated the antipsychotic-like effect of dopamine D2 receptor antagonists [161] . In addition, all antipsychotic drugs used in this study display high in vitro affinity for α 1 -adrenoceptors ( Table   1) , which suggests a potential antipsychotic role of α 1 -adrenoceptor antagonism in the pharmacotherapy of schizophrenia. However, the use of drugs that possess a high α 1 -adrenoceptor antagonism in vivo is limited because their cardiovascular side-effects (hypotension, arrhythmia).
In summary, the intra-mPFC administration of M100907, repinotan and prazosin prevents MK-801-induced increase in 5-HT and glutamate, effects that are comparable to those obtained with clozapine and olanzapine [62; present study], and can be associated to a direct reduction the excitability of a subpopulation of pyramidal neurons in the mPFC (Fig (8) ). Thus, it is possible that 5-HT 2A and α 1 -adrenergic receptor antagonism, as well as 5-HT 1A receptor agonism, may relate to a better treatment of most symptoms of schizophrenia.
In fact, preclinical studies have shown that 5-HT 2A antagonists and 5-HT 1A
agonists can alleviate cognitive deficits induced by NMDA receptor antagonists [61] . Because each of these receptor components do not confer antipsychotic properties individually, it is conceivable that a combined effect is necessary to achieve this goal.
In a recent work, Homayoun and Moghaddam demonstrated that
clozapine has the unique feature of increasing the activity of putative pyramidal neurons with low baseline firing rates and decreasing the activity of neurons with higher firing rates in prefrontal cortex [64] . [162, 163] . Clozapine has been shown to enhance dopamine D1 receptor-mediated neurotransmission [72, 164] . Therefore, the pro-cognitive action of clozapine could also result from its action on dopamine D1 receptors.
Alternatively, it has also been suggested that the action of clozapine could involve potentiation of NMDA transmission (see [165] GABAergic interneurons in prefrontal cortex play a critical role in cortical circuits by providing feedforward and feedback inhibition and synchronizing neuronal activity [172, 173] . In this regard, we also propose that blockade of 
